{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:23:02Z","timestamp":1790133782219,"version":"4.0.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) is biologically and clinically heterogeneous and would benefit from prognostic biomarkers to guide management. Circulating tumor DNA (ctDNA) is a novel prognostic biomarker in diffuse large B-cell lymphoma that may have applicability in MCL. We analyzed ctDNA dynamics in previously untreated patients with MCL who received induction therapy with bortezomib and DA-EPOCH-R for 6 cycles followed by random assignment to observation or bortezomib maintenance in responding patients in a prospective phase 2 study. Most patients also underwent initial treatment window of bortezomib alone prior to induction. Serum was collected pretreatment, after the window, after cycles 1 and 2, at the end of induction, and at each follow-up visit along with restaging computed tomography scans. Next-generation sequencing was used to identify and quantify ctDNA encoding the immunoglobulin receptor sequences in serum as markers of minimal residual disease. Fifty-three patients were enrolled, with a median follow-up of 12.7 years. Patients without detectable ctDNA after 2 cycles of induction had longer progression-free survival (PFS) and overall survival (OS) compared with those with detectable ctDNA (median PFS, 2.7 vs 1.8 years; overall P = .005; median OS, 13.8 vs 7.4 years; overall P = .03). Notably, in\u00a0vivo assessment of ctDNA dynamics during the bortezomib window was not prognostic, and there was no difference in PFS or OS with bortezomib maintenance. ctDNA monitoring after induction showed that molecular relapse preceded clinical relapse in some cases. In conclusion, interim ctDNA negativity strongly correlates with improved survival and supports the investigation of response-adapted strategies. This trial was registered at www.clinicaltrials.gov as #NCT00114738.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006397","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T19:58:45Z","timestamp":1644523125000},"page":"2667-2680","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-6844","authenticated-orcid":false,"given":"Rahul","family":"Lakhotia","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Georgetown University, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle","family":"Saba","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, LA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Bergvall","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Uniformed Services University of the Health Sciences, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Nicole","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Nursing, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Jacob","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Yusko","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Laboratory of Lymphoid Malignancies, National Heart, Lung and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"1","key":"2022042215221697400_B1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2022042215221697400_B2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol."},{"issue":"28","key":"2022042215221697400_B3","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol."},{"issue":"10044","key":"2022042215221697400_B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet."},{"issue":"7","key":"2022042215221697400_B5","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood."},{"issue":"32","key":"2022042215221697400_B6","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022042215221697400_B7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med."},{"issue":"13","key":"2022042215221697400_B8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2022042215221697400_B9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol."},{"issue":"2","key":"2022042215221697400_B10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell."},{"issue":"15","key":"2022042215221697400_B11","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022042215221697400_B12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood."},{"issue":"12","key":"2022042215221697400_B13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2022042215221697400_B14","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1182\/blood.V110.11.4490.4490","article-title":"Rituximab-EPOCH, an effective front-line therapy for mantle cell lymphoma [abstract]","volume":"110","author":"Palacios","year":"2007","journal-title":"Blood."},{"issue":"9","key":"2022042215221697400_B15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med."},{"issue":"10","key":"2022042215221697400_B16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022042215221697400_B17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022042215221697400_B18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601","volume":"172","author":"Till","year":"2016","journal-title":"Br J Haematol."},{"issue":"4","key":"2022042215221697400_B19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/10428194.2017.1365855","article-title":"Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study","volume":"59","author":"Drach","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022042215221697400_B20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica."},{"issue":"5","key":"2022042215221697400_B21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3324\/haematol.2016.152496","article-title":"Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study","volume":"102","author":"Verhoef","year":"2017","journal-title":"Haematologica."},{"issue":"6","key":"2022042215221697400_B22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ajh.25783","article-title":"Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB\/Alliance 50403","volume":"95","author":"Kaplan","year":"2020","journal-title":"Am J Hematol."},{"issue":"3","key":"2022042215221697400_B23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bjh.16567","article-title":"Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial","volume":"190","author":"Doorduijn","year":"2020","journal-title":"Br J Haematol."},{"issue":"6","key":"2022042215221697400_B24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood."},{"issue":"16","key":"2022042215221697400_B25","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022042215221697400_B26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica."},{"issue":"3","key":"2022042215221697400_B27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022042215221697400_B28","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/10428194.2017.1361032","article-title":"Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility","volume":"59","author":"Guidot","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022042215221697400_B29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"issue":"24","key":"2022042215221697400_B30","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2022042215221697400_B31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol."},{"issue":"6","key":"2022042215221697400_B32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia."},{"issue":"28","key":"2022042215221697400_B33","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022042215221697400_B34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med."},{"issue":"3","key":"2022042215221697400_B35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell."},{"issue":"16","key":"2022042215221697400_B36","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022042215221697400_B37","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol."},{"issue":"27","key":"2022042215221697400_B38","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022042215221697400_B39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer."},{"issue":"2","key":"2022042215221697400_B40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"7","key":"2022042215221697400_B41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann Nucl Med."},{"issue":"1","key":"2022042215221697400_B42","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project","volume":"105","author":"Bailly","year":"2020","journal-title":"Haematologica."},{"issue":"12","key":"2022042215221697400_B43","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/bloodadvances.2020004051","article-title":"Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma","volume":"5","author":"Nath","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"2022042215221697400_B44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol."},{"issue":"1","key":"2022042215221697400_B45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2022042215221697400_B46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1200\/JCO.18.01907","article-title":"Reply to J. Wang et\u00a0al","volume":"37","author":"Kurtz","year":"2019","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022042215221697400_B47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinchem\/hvaa103","article-title":"Plasma or serum: which is preferable for mutation detection in liquid biopsy?","volume":"66","author":"Pittella-Silva","year":"2020","journal-title":"Clin Chem."},{"issue":"1","key":"2022042215221697400_B48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML Workshop on ctDNA","volume":"38","author":"Rossi","year":"2020","journal-title":"Hematol Oncol."},{"key":"2022042215221697400_B49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136565","article-title":"Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: phase II, investigator-initiated, single-center study","volume":"136","author":"Epstein-Peterson","year":"2020","journal-title":"Blood."},{"issue":"364","key":"2022042215221697400_B50","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med."},{"issue":"12","key":"2022042215221697400_B51","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2667\/1892949\/advancesadv2021006397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2667\/1892949\/advancesadv2021006397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:23:45Z","timestamp":1650641025000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/8\/2667\/483956\/Circulating-tumor-DNA-predicts-therapeutic-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006397","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}